"Oncogene Proteins, Viral" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Products of viral oncogenes, most commonly retroviral oncogenes. They usually have transforming and often protein kinase activities.
| Descriptor ID |
D009856
|
| MeSH Number(s) |
D12.776.624.664.520 D12.776.964.700
|
| Concept/Terms |
Oncogene Proteins, Viral- Oncogene Proteins, Viral
- Viral Oncogene Proteins
- Viral Transforming Proteins
- Transforming Proteins, Viral
- v-onc Proteins
- v onc Proteins
|
Below are MeSH descriptors whose meaning is more general than "Oncogene Proteins, Viral".
Below are MeSH descriptors whose meaning is more specific than "Oncogene Proteins, Viral".
This graph shows the total number of publications written about "Oncogene Proteins, Viral" by people in this website by year, and whether "Oncogene Proteins, Viral" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 3 | 2 | 5 |
| 1995 | 3 | 1 | 4 |
| 1996 | 2 | 0 | 2 |
| 1997 | 4 | 1 | 5 |
| 1998 | 0 | 1 | 1 |
| 1999 | 4 | 0 | 4 |
| 2000 | 2 | 0 | 2 |
| 2001 | 1 | 1 | 2 |
| 2002 | 3 | 0 | 3 |
| 2003 | 3 | 0 | 3 |
| 2004 | 1 | 2 | 3 |
| 2005 | 2 | 2 | 4 |
| 2006 | 2 | 3 | 5 |
| 2007 | 3 | 0 | 3 |
| 2008 | 3 | 2 | 5 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 2 | 2 | 4 |
| 2012 | 1 | 1 | 2 |
| 2013 | 1 | 3 | 4 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 2 | 1 | 3 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 4 | 4 |
| 2021 | 1 | 1 | 2 |
| 2022 | 2 | 0 | 2 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Oncogene Proteins, Viral" by people in Profiles.
-
Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors. Invest New Drugs. 2023 04; 41(2):284-295.
-
Combined TRIP13 and Aurora Kinase Inhibition Induces Apoptosis in Human Papillomavirus-Driven Cancers. Clin Cancer Res. 2022 10 14; 28(20):4479-4493.
-
Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers. Cancer Immunol Res. 2022 02; 10(2):259-271.
-
Diverse tumorigenic consequences of human papillomavirus integration in primary oropharyngeal cancers. Genome Res. 2022 01; 32(1):55-70.
-
Germline determinants of humoral immune response to HPV-16 protect against oropharyngeal cancer. Nat Commun. 2021 10 12; 12(1):5945.
-
Endogenous YAP1 activation drives immediate onset of cervical carcinoma in situ in mice. Cancer Sci. 2020 Oct; 111(10):3576-3587.
-
Sustainable Tumor-Suppressive Effect of iPSC-Derived Rejuvenated T Cells Targeting Cervical Cancers. Mol Ther. 2020 11 04; 28(11):2394-2405.
-
Identifying epigenetic biomarkers of established prognostic factors and survival in a clinical cohort of individuals with oropharyngeal cancer. Clin Epigenetics. 2020 06 29; 12(1):95.
-
A PIK3CA transgenic mouse model with chemical carcinogen exposure mimics human oral tongue tumorigenesis. Int J Exp Pathol. 2020 02; 101(1-2):45-54.
-
Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV+ oral cancer. J Immunother Cancer. 2019 09 18; 7(1):252.